Loading stock data…
XNCR
$12.69+0.76 (+6.37%)
Market ClosedLast close May 1
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Xencor, Inc. in the Healthcare sector is trading at $12.69. The stock is currently 32% below its 52-week high of $18.69, remaining 3.6% above its 200-day moving average. Technical signals show neutral RSI of 56 and bearish MACD signal, explaining why XNCR maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$12.69
Potential Upside
5%
Whystock Fair Value$13.32
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$28.42+123.9%
Range$13.00 – $43.00
Fundamentals
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$942.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.92%
Volume
Today's trading volume
858,236
Recent News
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Corcept (CORT) delivered earnings and revenue surprises of -1.11% and -4.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls
Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of +86.00% and +30.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Xencor: Q4 Earnings Snapshot
PASADENA, Calif. AP) — Xencor Inc. XNCR) on Wednesday reported a loss of $6.7 million in its fourth quarter.
What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector
Xencor’s fair value estimate has been nudged up from about US$28.25 to roughly US$28.83 per share, with a slightly higher discount rate of around 7.50% and a modest lift in revenue growth assumptions to roughly 4.13%. These changes line up with a more supportive backdrop for U.S. biopharma, where stronger sector conditions, steadier deal activity and better access to capital are now being recognized in updated models, even as questions remain about how long these supports will hold. Stay...